SITE007-0335

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE007 (JPN) · Dr. Dubois
consented 2023-04-08

AEs

Serious

Dropout signal

–

Adverse events

severe serious assessed

Grade 3 Pruritus — outcome: RECOVERED/RESOLVED; onset 2023-06-04 (study day 52); relationship: not assessed; serious criteria: hospitalization

mild assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-09-12 (study day 152); relationship: not assessed

severe serious assessed

Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-04-21 (study day 374); relationship: not assessed; serious criteria: hospitalization

moderate assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-06-30 (study day 444); relationship: not assessed

Data queries

No data queries.